Related Experiment Video
Updated: Dec 26, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
Once-Monthly Subcutaneously Administered Risperidone in the Treatment of Schizophrenia: Patient Considerations
Lesia V Tchobaniouk1, Erin E McAllister2, Danielle L Bishop3
1Department of Pharmacy, North Memorial Health Hospital, Robbinsdale, MN, USA.
Abstract:
Adherence to antipsychotic medications is a major challenge in schizophrenia. Long-acting injectable antipsychotics have been shown to offer advantages over oral formulations. A new extended release formulation of risperidone for subcutaneous injection was developed to address issues of non-adherence. The aim of this manuscript was to compare the new subcutaneous formulation to currently available formulations of injectable risperidone and paliperidone to determine whether the novel delivery by subcutaneous injection may provide substantial benefits. A literature search was conducted using PubMed, OVID, and Cochrane Library electronic databases to assess the advantages and disadvantages of long-acting formulations of risperidone. Potential advantages of risperidone for subcutaneous injection include a simplified dosing and ease of administration. Potential disadvantages include injection site pain and medication cost.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Psychosis and Antipsychotic Drugs: Overview
Drug Dosing: Geriatric Patients
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

